Clinical Trials Logo
  1. Home
  2. Mutation
  3. NCT05864937

C677T Methylenetetrahydrofolate Reductase Mutation — C677T  

Mutation Clinical Trial

Official title:
Comparison of Two Preventive Treatments for Patients With Recurrent Miscarriages Carrying a C677T Methylenetetrahydrofolate Reductase Mutation: 5-year Experience

Clinical Trial Summary

To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation. In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3).

Clinical Trial Description

Recurrent miscarriage (RM) is defined as three or more consecutive spontaneous fetal losses and it affects 0.3% to 1% of pregnancies.To investigate the effect of anticoagulant treatment on pregnancy outcomes in patients with previous recurrent miscarriages (RM) who carry a methylenetetrahydrofolate reductase (MTHFR) gene mutation. In this longitudinal retrospective study, patients with RM were treated during pregnancy with either: (i) 100 mg/day aspirin and 5 mg/day folic acid (group 1); or the same protocol plus 0.4 mg/day enoxaparin (group 2). An age-matched group of triparous women without RM or thrombophilia was used as the control group (group 3). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05864937
Study type Observational
Source Centre Hospitalier Universitaire, Amiens
Contact
Status Completed
Phase
Start date December 1, 2011
Completion date September 28, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03902353 - Screening of Pulmonary Veino Occlusive Disease in Heterozygous EIF2AK4 Mutation Carriers N/A
Recruiting NCT03246841 - Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. N/A
Completed NCT04068961 - New Strategies of Genetic Study of Patients With Oculocutaneous Albinism
Recruiting NCT05954442 - Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype Phase 3
Active, not recruiting NCT03857594 - Integrative Sequencing In Germline and Hereditary Tumours
Active, not recruiting NCT04983628 - Molecular Profiling in Prostate Cancer
Recruiting NCT05446155 - BioMEL- Diagnostic and Prognostic Factors in Melanoma.
Completed NCT02612350 - Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Completed NCT02884063 - Utilizing Free DNA in Embryo Culture for PGT
Completed NCT02808715 - Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16 N/A
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Enrolling by invitation NCT04708639 - Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients
Recruiting NCT03125759 - The Association of Omentin and Ischemic Stroke N/A
Recruiting NCT05162508 - Impact of COVID-19 SARS-CoV-2 Variability in ICU Hospitalized Patients With Severe Disease
Recruiting NCT03786575 - Clinical Value of Next Generation Sequencing in Endocrine Therapy for Advanced Hormone Receptor Positive/HER-2 Negative Breast Cancer N/A
Recruiting NCT03702309 - Liquid Biopsy Evaluation and Repository Development at Princess Margaret